Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769264 | 0.95 | CHRM2 (0.39) | CHRM2MCHR1HDAC6SLC2A1TRPV4 | |
| SCHEMBL768889 | 0.95 | CHRM2 (0.39) | CHRM2MCHR1HDAC6SLC2A1TRPV4 | |
| SCHEMBL768563 | 0.90 | CHRM2 (0.38) | CHRM2MCHR1HDAC6SLC2A1TRPV4 | |
| SCHEMBL768447 | 0.89 | CHRM2 (0.35) | CHRM2MCHR1HDAC6SLC2A1HRH3 | |
| SCHEMBL767767 | 0.88 | HRH3 (0.41) | CHRM2SLC2A1HRH3CHRM3 | |
| SCHEMBL768533 | 0.88 | HRH3 (0.41) | CHRM2SLC2A1HRH3CHRM3 | |
| SCHEMBL768927 | 0.88 | DRD2 (0.36) | CHRM2MCHR1HRH3CCR2 | |
| SCHEMBL769140 | 0.88 | CHRM2 (0.36) | CHRM2MCHR1SLC2A1HRH3CCR2 | |
| SCHEMBL768953 | 0.88 | HRH3 (0.42) | CHRM2SLC2A1HRH3CHRM3 | |
| SCHEMBL768708 | 0.87 | CHRM2 (0.39) | CHRM2MCHR1HDAC6SLC2A1TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | CHRM2 2/4885MCHR1 239/4885HDAC6 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.